ReviewDrug delivery2019
Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy.
Review in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Drug Delivery Systems for the Treatment of Knee Osteoarthritis: A Systematic Review of In Vivo Studies.International journal of molecular sciences · 2021Pooled it
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Advances in drug delivery systems for Osteoarthritis therapy: exosomes, microparticles, nanoparticles, and hydrogels.Discover nano · 2026Review
- Synergistic Application of Mesenchymal Stem Cells and Anti-Inflammatory Therapeutics Within Hydrogel Matrices For Enhanced Treatment of Osteoarthritis and Promotion of Cartilage Regeneration.Macromolecular bioscience · 2026Article
- Extracellular Vesicles in Osteoarthritis: From Pathogenic Mediators to Engineered Therapeutics in a Precision Medicine Roadmap.Journal of extracellular biology · 2026Review
- From undruggable to degradable: A deep learning-enabled framework for precision orthopaedic protein degradation.Journal of orthopaedic translation · 2026Review
- Adaptive bilirubin nanoscavenger alleviates pulmonary oxidative stress and inflammation for acute lung injury therapy.Journal of advanced research · 2026Article
- Integrating superlubricative nanomaterials with precision drug delivery for advanced osteoarthritis therapy.Materials today. Bio · 2025Article
- Molecular signaling pathways in osteoarthritis and biomaterials for cartilage regeneration: a review.Bioengineered · 2025Review
- Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.Pharmaceutics · 2025Review
- The Application of Novel Drug Delivery Systems in the Treatment of Osteoarthritis.Pharmaceutics · 2025Review
- Drug Delivery Systems Targeting the Knee Microenvironment: A Prospective Strategy for Knee Osteoarthritis Treatment.Drug design, development and therapy · 2025Review
- New insights into the mechanisms and therapeutic strategies of chondrocyte autophagy in osteoarthritis.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Inflammation-Responsive Mesoporous Silica Nanoparticles with Synergistic Anti-inflammatory and Joint Protection Effects for Rheumatoid Arthritis Treatment.Pharmaceutical research · 2024Article
- Screening of poly-beta amino ester coated emulsion of ketorolac for cartilage delivery.Journal of materials chemistry. B · 2024Article
- Reproducible Synthesis of Biocompatible Albumin Nanoparticles Designed for Intra-articular Administration of Celecoxib to Treat Osteoarthritis.ACS applied materials & interfaces · 2024Article
- Engineering approaches for RNA-based and cell-based osteoarthritis therapies.Nature reviews. Rheumatology · 2024Review
- Functional Nanomaterials for the Treatment of Osteoarthritis.International journal of nanomedicine · 2024Review
- Polysaccharide-based hydrogels for cartilage regeneration.Frontiers in cell and developmental biology · 2024Review
- Anti-Osteoarthritis Mechanism of the Nrf2 Signaling Pathway.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a progressive and degenerative disease, which is no longer confined to the elderly. So far, current treatments are limited to symptom relief, and no valid OA disease-modifying drugs are available. Additionally, OA relative joint is challenging for drug delivery, since the drugs experience rapid clearance in joint, showing a poor bioavailability. Existing therapeutic drugs, like non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are not conducive for long-term use due to adverse effects. Though supplementations, including chondroitin sulfate and glucosamine, have shown beneficial effects on joint tissues in OA, their therapeutic use is still debatable. New emerging agents, like Kartogenin (KGN) and Interleukin-1 receptor antagonist (IL-1 ra), without a proper formulation, still will not work. Therefore, it is urgent to establish a suitable and efficient drug delivery system for OA therapy. In this review, we pay attention to various types of drug delivery systems and potential therapeutic drugs that may escalate OA treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.